We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-8.52%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$853M
AUM Growth
-$177M
Cap. Flow
+$51M
Cap. Flow %
5.98%
Top 10 Hldgs %
71.46%
Holding
37
New
3
Increased
4
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$27.3M
2
TVRD
Tvardi Therapeutics
TVRD
+$25.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.2M
4
MRSN
Mersana Therapeutics
MRSN
+$8.06M
5
NRIX icon
Nurix Therapeutics
NRIX
+$6.1M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$20.1M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$9.59M
3
OMEG
Omega Alpha SPAC Class A Ordinary Shares
OMEG
+$3.93M
4
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
2 Financials 3.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$119M 13.95%
4,831,307
– –
DVAX
2
DELISTED
Dynavax Technologies
DVAX
$106M 12.42%
8,415,000
– –
PHVS icon
3
Pharvaris
PHVS
$2.44B
$70.3M 8.24%
3,180,601
– –
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.18B
$63.9M 7.5%
3,000,000
-979,292
-25% -$20.1M
EQRX
5
DELISTED
EQRx, Inc. Common Stock
EQRX
$46.9M 5.5%
10,003,573
– –
NUVL
6
DELISTED
Nuvalent
NUVL
$46.5M 5.45%
3,428,014
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.92B
$43M 5.04%
2,305,558
+275,857
+14% +$5.51M
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
$40M 4.69%
346,547
+85,666
+33% +$8.06M
AMLX icon
9
Amylyx Pharmaceuticals
AMLX
$2.54B
$37.5M 4.4%
1,948,214
-807,836
-29% -$9.59M
RPID icon
10
Rapid Micro Biosystems
RPID
$86.2M
$36.3M 4.25%
8,434,560
– –
TVRD
11
Tvardi Therapeutics
TVRD
$23.4M
$24.2M 2.83%
+73,541
New +$25.8M
NRIX icon
12
Nurix Therapeutics
NRIX
$2.65B
$23.1M 2.71%
1,822,883
+538,570
+42% +$6.1M
TSVT
13
DELISTED
2seventy bio
TSVT
$18.6M 2.18%
1,408,901
– –
PTGX icon
14
Protagonist Therapeutics
PTGX
$9.44B
$17.9M 2.1%
+2,260,572
New +$27.3M
SVRA icon
15
Savara
SVRA
$1.19B
$17.7M 2.07%
11,622,598
– –
AVIR icon
16
Atea Pharmaceuticals
AVIR
$420M
$17.6M 2.07%
2,485,638
– –
CCCC icon
17
C4 Therapeutics
CCCC
$412M
$12.4M 1.45%
1,642,210
– –
ANNX icon
18
Annexon
ANNX
$886M
$12.2M 1.43%
3,241,628
– –
RACB
19
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$9.8M 1.15%
1,000,000
– –
TNGX icon
20
Tango Therapeutics
TNGX
$4.41B
$8.71M 1.02%
1,921,790
– –
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$5.03B
$8.46M 0.99%
+600,523
New +$11.2M
XLO icon
22
Xilio Therapeutics
XLO
$60.3M
$8.19M 0.96%
200,387
– –
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.93M 0.81%
1,431,058
– –
ARYD
24
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$6.87M 0.81%
700,000
– –
IVVD icon
25
Invivyd
IVVD
$218M
$6.35M 0.75%
1,937,207
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2022 Portfolio in Review

As of Q2 2022, Bain Capital Life Sciences Investors held 37 positions worth $853M, down 17% from $1.03B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Bain Capital Life Sciences Investors deployed $51M of net new capital in Q2 2022, opening 3 new positions and adding to 4 existing holdings. Its largest new stake was Protagonist Therapeutics: 2,260,572 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $20.1M trimmed.

  • Bain Capital Life Sciences Investors's largest Q2 2022 buy was Protagonist Therapeutics: 2,260,572 shares worth $17.9M.
  • Bain Capital Life Sciences Investors added most to Mersana Therapeutics in Q2 2022, an estimated $8.06M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2022 reduction was Arcutis Biotherapeutics, cutting an estimated $20.1M.
  • Bain Capital Life Sciences Investors fully exited Omega Alpha SPAC Class A Ordinary Shares in Q2 2022, selling an estimated $3.93M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 71% of its $853M portfolio in Q2 2022.
  • Bain Capital Life Sciences Investors opened 3 new positions and closed 2 in Q2 2022.
  • Bain Capital Life Sciences Investors's portfolio value fell 17% quarter-over-quarter to $853M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2022, filed 15 Aug 2022.